Henrik Otendal

Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic Lateral Sclerosis – ALS. TikoMed … Läs mer

Viken – October 11, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Jeremy Shefner, MD, PhD at the Gregory W. Fulton ALS & Neuromuscular Disease Center, the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA as the third member of its newly-formed Scientific Advisory Board. Professor Shefner … Läs mer

Viken – September 26, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Caroline Ingre, MD, PhD senior consultant neurology and Head of ALS at Karolinska University Hospital and Karolinska Institute as the second member of its newly-formed Scientific Advisory Board. Dr. Ingre runs the ALS clinic at Karolinska University Hospital and has … Läs mer

Viken – September 19, 2023 – Today, Swedish biopharmaceutical company TikoMed AB announced the formation of its Scientific Advisory Board (SAB). The SAB will work cohesively with management to advance the company’s clinical development of ILB, TikoMeds drug in Phase 2 development in ALS. The board will integrate highly experienced clinicians as well as seasoned … Läs mer

Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies Viken, Sweden – 13th September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company’s lead drug candidate ILB® to: inhibit infection of human cells by the … Läs mer

Viken, Sweden – 7th September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company’s lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine … Läs mer

Viken, Sweden – 31st August 2022 – TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body’s ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spectrum mechanism of action of TikoMed’s ILB® neuroprotective drug platform. In multiple preclinical and clinical … Läs mer

Viken – 3rd August 2022 – A new study with TikoMed’s lead drug candidate, ILB®, addressing underlying causes of neurodegeneration in acute and chronic diseases, was published in the International Journal of Molecular Sciences today. The data from the rodent model studying severe traumatic brain injury (sTBI), demonstrated that ILB® administration 30 minutes after sTBI … Läs mer

Viken – 25th May, 2022 – A new study with TikoMed’s platform lead clinical drug candidate ILB®, provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of Amyotrophic Lateral Sclerosis (ALS). The study was published in PLOS ONE today. In a phase II study … Läs mer